MAPT and frontotemporal dementia: Therefore, while [18F]AV‐1451 might retain a role in tracking disease by visualising the distribution and/or severity of neuropathology in a person with frontotemporal dementia, it is unlikely to have utility for cohort selection for disease modifying trials that target tau or TDP‐43‐specific disease mechanisms.